U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT07464587) titled 'Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease' on March 07.
Brief Summary: To evaluate the safety of inhaled TQC3721 Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Chronic Obstructive Pulmonary Disease
Intervention:
DRUG: TQC3721 Suspension for Inhalation
TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Published by HT D...